Ketogenic Dietary Interventions in Metabolic Disorders

Ketogenic diets (KDs) are characterised by a pronounced reduction in carbohydrate intake and a proportional increase in dietary fats, leading to a metabolic state known as ketosis in which the liver produces ketone bodies for energy. Originally devised for refractory epilepsy in the early 20th century, these interventions have attracted renewed interest for their ability to induce rapid weight loss, improve glycaemic control, and ameliorate features of metabolic syndrome. By shifting substrate utilisation from glucose to ketone bodies such as β-hydroxybutyrate and acetoacetate, KDs modulate key pathways involved in insulin sensitivity, lipid oxidation and inflammatory signalling. Clinically, these diets have demonstrated reductions in fasting glucose, haemoglobin A1c and visceral adiposity, alongside decreased reliance on pharmacological treatments. Mechanistic studies implicate receptors such as hydroxycarboxylic acid receptor 2 and modulation of intracellular messengers such as cyclic adenosine monophosphate in the beneficial effects of ketone bodies on insulin resistance. Beyond classical metabolic disorders, ketogenic approaches are under investigation in polycystic ovary syndrome, non-alcoholic fatty liver disease and neurodegenerative conditions, where alterations in energy metabolism and inflammation underpin disease progression. Advancements in digital health platforms now facilitate continuous monitoring of nutritional ketosis, enhancing long-term adherence and clinical outcomes. Ongoing research aims to refine diet composition, personalise regimens via genetic and microbiome profiling, and clarify long-term safety across diverse populations.

Research from Nature Portfolio

Recent clinical findings have explored whether genetic profiling can inform optimal macronutrient composition for weight management. In a genotype-informed trial, individuals categorised as fat-responders or carbohydrate-responders underwent 12 weeks of weight-loss intervention on high-fat or high-carbohydrate diets. Weight change did not differ between genotype-concordant and genotype-discordant groups, suggesting that current genetic stratification offers limited predictive value for macronutrient efficacy. In preclinical models, ketogenic feeding initiated in young mice preserved neurovascular integrity and elevated concentrations of beneficial gut bacteria. After 16 weeks on a ketogenic regimen, animals exhibited increased cerebral blood flow, enhanced blood–brain barrier transport proteins, reduced mechanistic target of rapamycin signalling and augmented endothelial nitric oxide synthase expression. Concurrent shifts in the gut microbiome towards mucin-degrading and lactate-producing taxa indicate a bidirectional interaction between ketosis and microbial ecology, with implications for cognitive resilience and systemic metabolic health.

Ketogenic Dietary Interventions in Metabolic Disorders publication trend

The graph below shows the total number of articles in ketogenic dietary interventions in metabolic disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Ketosis: A metabolic state characterised by elevated blood concentrations of ketone bodies resulting from increased fatty acid oxidation.

Ketone bodies: Water-soluble molecules (β-hydroxybutyrate, acetoacetate) produced by the liver during periods of low carbohydrate availability to serve as alternative energy substrates.

Nutritional ketosis: A controlled ketosis induced by dietary carbohydrate restriction to achieve therapeutic metabolic effects without diabetic ketoacidosis.

Insulin resistance: A diminished response of target tissues to circulating insulin, leading to impaired glucose uptake and hyperglycaemia.

Hydroxycarboxylic acid receptor 2 (HCAR2): A G-protein-coupled receptor activated by β-hydroxybutyrate that mediates metabolic and anti-inflammatory responses in adipose tissue.

References

1. 3-Hydroxybutyrate ameliorates insulin resistance by inhibiting PPARγ Ser273 phosphorylation in type 2 diabetic mice. Signal Transduction and Targeted Therapy (2023).
2. The Personalized Nutrition Study (POINTS): evaluation of a genetically informed weight loss approach, a Randomized Clinical Trial. Nature Communications (2023).
3. Ketogenic diet enhances neurovascular function with altered gut microbiome in young healthy mice. Scientific Reports (2018).
4. Ketogenic Diet as a Possible Non-pharmacological Therapy in Main Endocrine Diseases of the Female Reproductive System: A Practical Guide for Nutritionists. Current Obesity Reports (2023).
5. Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-Year Non-randomized Clinical Trial. Frontiers in Endocrinology (2019).
6. (d)-β-Hydroxybutyrate Inhibits Adipocyte Lipolysis via the Nicotinic Acid Receptor PUMA-G*. Journal of Biological Chemistry (2005).
7. Beyond weight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets. European Journal of Clinical Nutrition (2013).